Evolving Leukemia Markers: Diagnosis, Prognosis, Therapy
*Corresponding Author: Rajat Mehra, AIIMS Diagnostic Oncology Center, India, Email: rmehra@aiimsdiagnostics.ac.inReceived Date: Nov 01, 2025 / Accepted Date: Dec 01, 2025 / Published Date: Dec 01, 2025
Citation: Mehra R (2025) Evolving Leukemia Markers: Diagnosis, Prognosis, Therapy. jcd 09: 322.DOI: 10.4172/2476-2253.1000322
Copyright: © 2025 Rajat Mehra This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,distribution and reproduction in any medium, provided the original author and source are credited.
Abstract
This compilation examines key molecular, epigenetic, and immunophenotypic markers in acute and chronic leukemias. \textit{It
covers emerginggenetic alterations} (TP53, IDH1/2), minimal residual disease (MRD), andmicroRNAs(miRNAs)inAcuteMyeloid
Leukemia(AML)andAcuteLymphoblasticLeukemia(ALL).TheanalysisalsoaddressesBCR-ABL1inChronicMyeloidLeukemia
(CML) and mechanisms of drug resistance. These markers are crucial for refining risk stratification, improving diagnostic accuracy,
guiding targeted therapies, and enhancing prognostic assessment across various leukemia subtypes, ultimately aiming for better
patient outcomes.
